Dan Wildman is a Strategic Advisor to PanTher Therapeutics. A seasoned executive with more than 35 years of experience in the MedTech industry, Dan is President & Chief Executive Officer of Wildman Ventures, LLC. He also currently serves as a member of the Board of Directors or as a Strategic Adviser for several early-stage organizations.
Prior to joining PanTher Therapeutics, Dan led the Digital Surgery Strategy initiative at Johnson & Johnson and served as worldwide President of Depuy Synthes Spine, the second-largest spine surgery business in the world. Previously, he served as Worldwide President of Ethicon Biosurgery, a division of Ethicon, Inc. While at Ethicon Biosurgery, he led the development and commercialization of a novel combination product based on a biomaterial and biologic formulation. The biosurgery business at Ethicon now exceeds $1.7B in revenue and continues to be one of the fastest-growing companies in J&J’s medical device portfolio.
As a strategic advisor to PanTher, Dan applies this expertise and his decades of experience to advancing the clinical development program for PTM-101 and selecting and prioritizing other Sagittari™ platform product candidates.
Dan holds a BA in Economics from St. Lawrence University.